Regenerative Medicine Group Says Cures Act Will Help Industry

The 21st Century Cures Act will require US FDA to create standards and an expedited approval process for regenerative medicine products. Trade group ARM supports the efforts.

Manufacturers of regenerative medicine products will get a welcome boost from US FDA under the 21st Century Cures Act, says Michael Werner, executive director of trade group the Alliance for Regenerative Medicine

Several clauses within the legislation, which was approved by the House on Nov. 30 and is expected to...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Legislation

More from Policy & Regulation